P1310 Hepatocellular Carcinoma (Hcc) Invading Portal Venous System in Cirrhosis: 7 Year Results of Percutaneous Radiofrequency Ablation of HCC and Main Portal Vein Tumor Thrombus (Mpvtt)

Giorgio, Antonio; Calisti, G; Coppola, Carmine; Scarano, Ferdinando; Scognamiglio, U.; Farella, Nunzia; Montesarchio, Luca; Stefano, G. de; Gatti, Pietro; Giorgio, Valentina

doi:10.1016/s0168-8278(14)61477-x

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, the incidence of gastric varices was higher in NAFLD associated cirrhosis than other groups in our cohort. It has also been reported that the incidence of portal vein thrombosis rises to 10%-40% in cirrhotic patients upon developing HCC [42] . Consistently, our study showed an elevated incidence of portal vein thrombosis in cirrhotic patients with hepatitis C or B after they developed HCC.…”

Section: Discussionmentioning

confidence: 94%

Significant cohort of non-alcoholic fatty liver disease with portal vein thrombosis in transplant waiting list

Basaranoglup¹

2018

J Liver

View full text Add to dashboard Cite

Author contributions: Basaranoglu M was involved in the study concept and design; study supervision, data acquisition, analysis and interpretation; drafting of the manuscript; critical revision of the manuscript for important intellectual content; raising fund; and providing administrative, technical, and material support; Demirbag AE performed statistical analysis; Najjar SM critically analyzed and reviewed data analysis and interpretation, and provided critical revision of the manuscript for important intellectual content; Sentürk H approved the final version of the manuscript.

show abstract

Section: Discussionmentioning

confidence: 94%

Significant cohort of non-alcoholic fatty liver disease with portal vein thrombosis in transplant waiting list

Basaranoglup¹

2018

J Liver

View full text Add to dashboard Cite

show abstract

“…The addition of TACE to sorafenib improved a median survival of 5.8 months, in a large cohort of 2112 eligible Child-Pugh A advanced HCC patients with macro-vascular invasion or nodal/distant metastases (10). In a single-center retrospective study involving 57 patients who had a single HCC lesion (≤5 cm) with the main PVTT, RFA of both the HCC and main PVTT significantly prolonged the long-term survival compared to non-treatment (1-year cumulative survival rate: 63% vs 0%, p<0.001) (15). Another retrospective analysis of 134 HCC patients with PVTT whose liver tumor sizes ranged from 2.2 to 16.5 cm revealed a median OS of 29.5 months with TACE combined with RFA (16).…”

Section: Introductionmentioning

confidence: 99%

Percutaneous Radiofrequency Ablation Combined With Transarterial Chemoembolization Plus Sorafenib for Large Hepatocellular Carcinoma Invading the Portal Venous System: A Prospective Randomized Study

et al. 2020

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) portends a worse prognosis. The objective of this study was to compare the efficacy of percutaneous radiofrequency ablation (RFA) combined with transarterial chemoembolization (TACE) plus sorafenib to that of the most commonly utilized regimen of TACE plus sorafenib in large HCCs with type I/II PVTT. Methods: An open-label, single-center, prospective, randomized trial of participants with tumors ≥5 cm and type I/II PVTT was performed. Participants with previously untreated HCCs were divided into two groups: RFA + cTACE + sorafenib (study group, n = 40) and cTACE + sorafenib (control group, n = 40). The primary endpoint was the objective response rate (ORR), the secondary endpoints included the overall survival (OS); time to progression (TTP); and toxicity. Prognostic factors were analyzed using cox-regression analysis. Results: 80 patients were enrolled into this study with integrated clinical data. Under a median follow-up of 506 days, the median age was 57.5 years (range: 28-80 years). The ORR of study group was higher than control group (70% vs 22.5%, p<0.001). Furthermore, the median OS of study group was superior to that of control group (468 days vs 219 days, HR: 0.44 [95% CI: 0.25-0.78], P = 0.005). Adverse events occurred with 100% probability in both groups (p>0.99), but no treatment-related deaths were recorded. Tumor encapsulation and attaining treatment response predict favorable OS in a multivariate Cox model. The rates of adverse events in both groups were 100% (p>0.99). There were no treatment-related deaths.

show abstract

P1310 Hepatocellular Carcinoma (Hcc) Invading Portal Venous System in Cirrhosis: 7 Year Results of Percutaneous Radiofrequency Ablation of HCC and Main Portal Vein Tumor Thrombus (Mpvtt)

Cited by 2 publications

References 0 publications

Significant cohort of non-alcoholic fatty liver disease with portal vein thrombosis in transplant waiting list

Significant cohort of non-alcoholic fatty liver disease with portal vein thrombosis in transplant waiting list

Percutaneous Radiofrequency Ablation Combined With Transarterial Chemoembolization Plus Sorafenib for Large Hepatocellular Carcinoma Invading the Portal Venous System: A Prospective Randomized Study

Contact Info

Product

Resources

About